Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
University of California, San Francisco |
---|---|
Information provided by: | University of California, San Francisco |
ClinicalTrials.gov Identifier: | NCT00734682 |
This is a Phase I study of Nanoliposomal CPT-11 in patients with Recurrent high-grade gliomas. Patients must have a histologically proven intracranial malignant glioma, which includes glioblastoma multiforme (GBM), gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified). Patients who are wild type or heterozygous for the UGT1A1*28 gene will received Nanoliposomal CPT-11. The total anticipated accrual will be approximately 36 patients (depending upon the actual MTD). The investigators hypothesis is that this new formulation of CPT-11 will increase survival over that seen in historical controls who have recurrent gliomas because CPT-11 will be encapsulated in a liposome nanoparticle, which has been seen to reduce toxicities from the drug.
Condition | Intervention | Phase |
---|---|---|
Glioblastoma Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Anaplastic Mixed Oligoastrocytoma Malignant Astrocytoma NOS |
Drug: Nanoliposomal CPT-11 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Single Group Assignment, Safety Study |
Official Title: | A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas |
Estimated Enrollment: | 36 |
Study Start Date: | August 2008 |
Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Malignant glioma include glioblastoma multiforme (GBM), Gliosarcoma (GS), anaplastic astrocytoma (AA), anaplastic oligodendroglioma (AO), anaplastic mixed oligoastrocytoma (AMO), or malignant astrocytoma NOS (not otherwise specified).
Patients must be registered in UCSF Cancer Center database prior to treatment with study drug.
Patients must have a Karnofsky performance status of > 60.
If the steroid dose is increased between the date of imaging and registration, a new baseline MRI/CT is required on a stable steroid dosage for at least 5 days.
Exclusion Criteria:
Contact: Valerie A Kivett, BS | 415-353-2076 | kivettv@neurosurg.ucsf.edu |
United States, California | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Principal Investigator: Michael Prados, MD |
Principal Investigator: | Michael Prados, MD | University of California, San Francisco |
Responsible Party: | University of California, San Francisco ( Michael Prados, MD ) |
Study ID Numbers: | 08103 |
Study First Received: | August 13, 2008 |
Last Updated: | August 18, 2009 |
ClinicalTrials.gov Identifier: | NCT00734682 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Glioblastoma Gliosarcoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma |
Anaplastic Mixed Oligoastrocytoma Malignant Astrocytoma NOS Nanoliposomal CPT-11 liposomal irinotecan |
Glioblastoma Astrocytoma Irinotecan Recurrence Neuroectodermal Tumors Malignant Astrocytoma Neoplasms, Germ Cell and Embryonal |
Neuroepithelioma Oligodendroglioma Glioma Gliosarcoma Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |
Glioblastoma Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action Astrocytoma Antineoplastic Agents Neoplasms, Nerve Tissue Irinotecan Enzyme Inhibitors Pharmacologic Actions Neuroectodermal Tumors |
Neoplasms Therapeutic Uses Neoplasms, Germ Cell and Embryonal Oligodendroglioma Glioma Gliosarcoma Neoplasms, Neuroepithelial Antineoplastic Agents, Phytogenic Neoplasms, Glandular and Epithelial |